A Prognostic Model for Drug-induced Liver Injury in China

Summary

A prospective, multi-center, non-interventional cohort study is going to conduct to explore the clinical characteristics, culprit drug(s) or herb(s), outcomes and risk factors of Drug-induced liver injury (DILI) in China and screen novel serum markers.

A prognostic model incorporating with the novel serum marker(s) for DILI would be established and validated to imporve the prognosis of patients in China .

Conditions

• Drug-induced Liver Injury

Sponsors & Collaborators

• Beijing Friendship Hospital

  lead OTHER

Principal Investigators

• Xinyan Zhao · Beijing Friendship Hospital

• Zhengsheng Zou · Beijing 302 Hospital

• Yu Chen · Beijing You 'an Hospital, Capital Medical University

• Juan Li · Qinghai People's Hospital

• Pingying Li · Qinghai People's Hospital

• Xiaoju Liu · Qinzhou First People's Hospital

• Liang Wang · Lanzhou University Second Hospital

• Juan Luo · Hebei CNPC Central Hospital

• Huahua Wang · Jiaozuo People's Hospital

• Hui Wang · Jiaozuo People's Hospital

• Jikang Yang · Jiaozuo People's Hospital

• Doudou Hu · Qingdao Municipal Hospital

• Qiuju Tian · The Affiliated Hospital of Qingdao University

• Rongkuan Li · The Second Affiliated Hospital of Dalian Medical University

• Lu Li · Peking University Third Hospital

• Liuyi Chang · Yuncheng Central Hospital

• Lu Zhang · Beijing Ditan Hospital

• Yuanjiao Gao · Beijing Ditan Hospital

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-05-25

Primary Completion

2026-12-31

Completion

2028-12-31

Countries

• China

Study Locations